Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands by Annemarie Voss, Elisabeth Smits, Karin M. A. Swart, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Ron M. C. Herings, Tania Schink, Ulrike Haug

Get full text

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. by Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez

Get full text

Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe by Luis Alberto García Rodríguez, Montse Soriano-Gabarró, Pareen Vora, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Ana Ruigomez, Leif Friberg, Ron Herings, Karin M A Swart, Tania Schink, Elisabeth Smits, Annemarie Voss, Christine Tarenz, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya

Get full text

Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study by Øystein Karlstad, Alexander Egeberg, Kari Furu, Ulrike Haug, Wiebke Schäfer, Johan Reutfors, Mette Reilev, Jesper Hallas, Ron Herings, Valeria Belleudi, Gianluca Trifirò, Rosa Gini, Ursula Kirchmayer, Henrik Støvring, Peter Bjødstrup Jensen, Lise Skov Ranch, Karin Gembert, David Hagg, Sarina Schwartz, Elisabeth Smits, Emily Holthius, Alessandro Cesare Rosa

Get full text